ISSF3 funding: Generation of a constitutive Cas9 pig for gene-level pharmaceutical target validation.

Baillie, Kenneth (Principal Investigator)
Clohisey Hendry, Sara (Co-investigator)
Lillico, Simon (Co-investigator)

Description

Creation of a porcine line that expressed Cas9-GFP ubiquitously, and the required tools, allowing for in situ, tissue specific genome editing in a live animal.

Status	Finished
Effective start/end date	1/07/18 → 30/06/20

1 Article

Human ACE2 transgenic pigs are susceptible to SARS-CoV-2 and develop COVID-19-like disease
Chau, L. F., Lillico, S., Opriessnig, T., Blake, R., Tardy, L., Lee, C.-H., Maxwell, S., Warren, C., Thornton, E., McLaughlin, C. L., McLachlan, G., Tait-Burkard, C., Fletcher, S., Anderson, S. P., Brown, S., Gibbard, L., Tzelos, T., MacMillan-Christensen, D., Baillie, J. K. & David, D. & 2 others, J Griffiths, D. & Grey, F., 17 Jan 2025, In: Nature Communications. 16, 1, p. 1-13 13 p., 766.
Research output: Contribution to journal › Article › peer-review

Open Access
File

ISSF3 funding: Generation of a constitutive Cas9 pig for gene-level pharmaceutical target validation.

Project Details

Description

Fingerprint

Human ACE2 transgenic pigs are susceptible to SARS-CoV-2 and develop COVID-19-like disease

ISSF3 funding: Generation of a constitutive Cas9 pig for gene-level pharmaceutical target validation.

Project Details

Description

Fingerprint

Research output

Human ACE2 transgenic pigs are susceptible to SARS-CoV-2 and develop COVID-19-like disease